InnovAge (INNV) Stock Price, News & Analysis

Company Overview

InnovAge Holdings, Inc. (NASDAQ:INNV) is a healthcare services company that specializes in caring for seniors through the Program of All-Inclusive Care for the Elderly (PACE). Designed for individuals who are eligible for both Medicare and Medicaid, the PACE model integrates medical care, social services and long-term care—delivered primarily in participants’ homes and community-based centers. InnovAge’s approach centers on interdisciplinary care teams that coordinate everything from primary and specialty medical services to nutritional counseling and recreational activities.

The company’s core offerings include comprehensive in-home assessments, physician and nursing services, physical and occupational therapy, prescription medication management, and transportation to medical appointments. InnovAge also manages adult day health centers where participants can receive social engagement activities, meals and group therapy sessions. By combining preventive care and chronic disease management with supportive social services, InnovAge aims to reduce hospitalizations and nursing home admissions among high-risk seniors.

Founded in 2014 and headquartered in Denver, Colorado, InnovAge operates a network of PACE centers across California, Colorado and Texas. The company serves urban and rural communities, adapting its care delivery model to address regional demographics and healthcare infrastructure. Supported by a management team with extensive experience in geriatrics, community health and healthcare operations, InnovAge continues to expand its footprint while maintaining regulatory compliance and quality standards set by state and federal authorities.

Key Stats

• Today's Range: $7.84 to $8.22
• 50-Day Range: $7.59 to $10.60
• 52-Week Range: $2.84 to $10.69
• Volume: 274,475 shs
• Average Volume: 216,425 shs
• Market Capitalization: $1.08 billion
• P/E Ratio: 159.23
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Reduce

InnovAge Stock Analysis - MarketRank™

InnovAge scored higher than 28% of companies evaluated by MarketBeat, and ranked 711th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.4 / 5
• Analyst Rating: Reduce

Consensus Rating

InnovAge has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 1 sell rating.

Downside Risk

InnovAge has a consensus price target of $7.00, representing about 12.1% downside from its current price of $7.96.

Amount of Analyst Coverage

InnovAge has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 36.00%

Earnings Growth

Earnings for InnovAge are expected to grow by 36.00% in the coming year, from $0.25 to $0.34 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of InnovAge is 159.23, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.28.

Price to Earnings Ratio vs. Sector

The P/E ratio of InnovAge is 159.23, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 29.02.

Price to Book Value per Share Ratio

InnovAge has a P/B Ratio of 4.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.52% of the float of InnovAge has been sold short.

Short Interest Ratio / Days to Cover

InnovAge has a short interest ratio ("days to cover") of 2.65, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in InnovAge has recently increased by 22.42%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

InnovAge does not currently pay a dividend.

Dividend Growth

InnovAge does not have a long track record of dividend growth.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.19

News Sentiment

InnovAge has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for InnovAge this week, compared to 2 articles on an average week.

Search Interest

11 people have searched for INNV on MarketBeat in the last 30 days. This is an increase of 38% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added InnovAge to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, InnovAge insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.00% of the stock of InnovAge is held by insiders.

Percentage Held by Institutions

12.26% of the stock of InnovAge is held by institutions.

INNV Stock Analysis - Frequently Asked Questions

How have INNV shares performed this year?

InnovAge's stock was trading at $5.19 at the beginning of 2026. Since then, INNV stock has increased by 53.4% and is now trading at $7.96.

How were InnovAge's earnings last quarter?

InnovAge Holding Corp. (NASDAQ:INNV) released its quarterly earnings results on Tuesday, May, 5th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by $0.28. The company earned $251.94 million during the quarter, compared to analyst estimates of $234.35 million. InnovAge had a net margin of 0.71% and a trailing twelve-month return on equity of 2.60%.
Read the conference call transcript.

When did InnovAge IPO?

InnovAge (INNV) raised $342 million in an initial public offering (IPO) on Thursday, March 4th 2021. The company issued 16,666,667 shares at $20.00-$21.00 per share. J.P. Morgan, Barclays, Goldman Sachs and Citigroup acted as the underwriters for the IPO and Baird, William Blair, Piper Sandler, Capital One Securities, Loop Capital Markets, Siebert Williams Shank and Roberts & Ryan were co-managers.

Who are InnovAge's major shareholders?

InnovAge's top institutional shareholders include Hillsdale Investment Management Inc. (0.39%), Ritholtz Wealth Management (0.18%), Inspire Investing LLC (0.15%) and Strs Ohio (0.05%). Insiders that own company stock include Nicole Damato, Michael Anthony Scarbrough, Richard C Zoretic and Richard C Zoretic.
View institutional ownership trends.

How do I buy shares of InnovAge?

Shares of INNV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of InnovAge own?

Based on aggregate information from My MarketBeat watchlists, some other companies that InnovAge investors own include EEStor Co. (ESU.V) (ESU), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), NVIDIA (NVDA), Meta Platforms (META) and Netflix (NFLX).

Company Calendar

• Today: 5/05/2026
• Last Earnings: 5/05/2026
• Next Earnings (Estimated): 5/05/2026
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:INNV
• Previous Symbol: OTCMKTS:INNV
• CIK: 1834376
• Web: www.innovage.com
• Phone: 844-803-8745
• Fax: N/A
• Employees: 2,440
• Year Founded: 1990

Price Target and Rating

• Average Price Target for InnovAge: $7.00
• High Price Target: $7.00
• Low Price Target: $7.00
• Potential Upside/Downside: -12.1%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.05
• Trailing P/E Ratio: 159.23
• Forward P/E Ratio: 31.84
• P/E Growth: N/A
• Net Income: -$30.31 million
• Net Margins: 0.71%
• Pretax Margin: 0.56%
• Return on Equity: 2.60%
• Return on Assets: 1.23%

Debt

• Debt-to-Equity Ratio: 0.24
• Current Ratio: 1.26
• Quick Ratio: 1.26

Sales & Book Value

• Annual Sales: $853.70 million
• Price / Sales: 1.27
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.76 per share
• Price / Book: 4.52

Miscellaneous

• Outstanding Shares: 135,700,000
• Free Float: 134,342,000
• Market Cap: $1.08 billion
• Optionable: Optionable
• Beta: 0.49